Bibliografia e referências

Crude and age-adjusted prevalence of diagnosed diabetes per 100 population, Estados Unidos, 1980-2002. Recurso de saúde pública sobre diabetes, site dos Centros de Controle e Prevenção de Doenças. Disponível em: http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm. Acessado em 17 de dezembro de 2004.

Epilepsy: One of the nation's most common disabling neurological conditions. Site dos Centros de Controle e Prevenção de Doenças. Disponível em: http://www.cdc.gov/epilepsy. Acessado em 17 de dezembro de 2004.

Fisher A, Fox J. Newborn screening for lysosomal storage disorders [informativo]. National MPS Society, Inc. 2004. Disponível em: http://www.mpssociety.org/lib-factsheet.html. Acessado em 17 de dezembro de 2004.

Fletcher J, Pamula Y, Martin AJ. Reversing respiratory disease in MPS: lessons from bone marrow transplantation. Poster acessado em www.chempathadelaide.com.au.

Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) J Pediatr. 2004;144:574-580.

Lee V, Li CK, Shing MM, et al. Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant. 2000;26:455-458.

Maroteaux P, Leveque B, Marie J, Lamy M. [Nova disostose com eliminação urinária de sulfato de condroitina B] Presse Med. 1963;71:1849-1852. Francês.

McGovern MM, Ludman MD, Short MP, et al. Bone marrow transplantation in Maroteaux-Lamy syndrome (MPS type 6): status 40 months after BMT. Birth Defects Orig Artic Ser. 1986;22:41-53.

Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.

Miller G, Partridge A. Mucopolysaccharidosis type VI presenting in infancy with endocardial fibroelastosis and heart failure. Pediatr Cardiol. 1983;4:61-62.

MPS I survey results: patterns in the referral, diagnosis, and management of individuals with MPS I. National MPS Society and Genzyme Corporation. Abril de 2004. Disponível em: http://www.mpssociety.org/library.html.

Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004;144(5 Suppl):S27-S34. Revisão.

Neufeld EF, Muenzer J. The mucopolysaccharidoses. Em: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol 3. 8ª. edição Nova York, NY: McGraw-Hill; 2001:3421-3452.

Paterson DE, Harper G, Weston HJ, Mattingley J. Maroteaux-Lamy syndrome, mild formMPS vi b. Br J Radiol. 1982;55:805-812.

Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151-156.

Rhodes L, Bailey CM, Moorman JE. Asthma prevalence and control characteristics by race/ethnicityUnited States, 2002. Morbidity and Mortality Weekly Report. 27 de fevereiro de 2004; 53:145-148. Disponível em: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5307a1.htm. Acessado em 17 de dezembro de 2004.

Sjogren P, Pedersen T, Steinmetz H. Mucopolysaccharidoses and anaesthetic risks. Acta Anaesthesiol Scand. 1987;31:214-218. Revisão.

Smith KS, Hallett KB, Hall RK, et al. Mucopolysaccharidosis: MPS VI and associated delayed tooth eruption. Int J Oral Maxillofac Surg. 1995;24:176-180.

Swiedler SJ, Beck M, Bajbouj M, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet; 2005:134A:144-150.

Vougioukas VI, Berlis A, Kopp MV, et al. Neurosurgical interventions in children with Maroteaux- Lamy syndrome. Case report and review of the literature. Pediatr Neurosurg. 2001;35:35-38. Revisão.

Wilcox WR. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr. 2004;144(5 Suppl):S3-S14. Revisão.